AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual…
Pharmaceuticals, Biotechnology and Life Sciences
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual…
Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services categoryPRINCETON, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) —…
Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen…
– First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector…
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial…
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza, SARS-CoV-2, rhinovirus, RSV and pneumonia-…
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that…
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery,…
ERAS-801’s CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII and wildtype alterationsImproved outcomes in…
SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…